# A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension

> **NCT06749236** · PHASE1 · COMPLETED · sponsor: **Vigonvita Life Sciences** · enrollment: 18 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** test formulation(T) 200 mg deuteriumremidvir hydrobromide for suspension
- **DRUG:** reference formulation(R) 100 mg deuteriumremidvir hydrobromide for suspension

## Key facts

- **NCT ID:** NCT06749236
- **Lead sponsor:** Vigonvita Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2025-08-11
- **Primary completion:** 2025-08-20
- **Final completion:** 2025-09-03
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06749236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06749236, "A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06749236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*